We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $127.07, marking a +0.56% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.28%.
Heading into today, shares of the company had gained 1.4% over the past month, lagging the Medical sector's gain of 2.77% and the S&P 500's gain of 3.07% in that time.
Investors will be hoping for strength from CRSP as it approaches its next earnings release. In that report, analysts expect CRSP to post earnings of -$1.68 per share. This would mark a year-over-year decline of 27.27%. Meanwhile, our latest consensus estimate is calling for revenue of $4.96 million, up 3206.67% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.88 per share and revenue of $907.14 million, which would represent changes of +192.25% and +126069.07%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRSP. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRSP currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CRSP currently has a Forward P/E ratio of 25.9. This represents a discount compared to its industry's average Forward P/E of 27.05.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 202, putting it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $127.07, marking a +0.56% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.28%.
Heading into today, shares of the company had gained 1.4% over the past month, lagging the Medical sector's gain of 2.77% and the S&P 500's gain of 3.07% in that time.
Investors will be hoping for strength from CRSP as it approaches its next earnings release. In that report, analysts expect CRSP to post earnings of -$1.68 per share. This would mark a year-over-year decline of 27.27%. Meanwhile, our latest consensus estimate is calling for revenue of $4.96 million, up 3206.67% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.88 per share and revenue of $907.14 million, which would represent changes of +192.25% and +126069.07%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRSP. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRSP currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CRSP currently has a Forward P/E ratio of 25.9. This represents a discount compared to its industry's average Forward P/E of 27.05.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 202, putting it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.